| abstract |
Disclosed herein are unnatural amino acids and dolastatin analogs comprising at least one unnatural amino acid, as well as methods of making the unnatural amino acids and polypeptides. The dolastatin analogs can include a variety of possible functional groups, but typically have at least one oxime, carbonyl, dicarbonyl and/or hydroxylamine group. Also disclosed herein are analogs of the unnatural amino acid dolastatin that have undergone further post-translational modifications, methods for achieving the modifications, and methods for purifying the analogs of dolastatin. Modified dolastatin analogs typically include at least one oxime, carbonyl, dicarbonyl and/or hydroxylamine group. Further disclosed are methods of using the non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnological uses. |